“One small way I am personally contributing to education is through sharing my take on academic and industry articles, using my medical background to boil down the jargon and pull out the benefits of the news for you.”

- Dan Platt, M.D.
Chief Medical Officer

Our Deskside with Dr. Dan section highlights cancer news in a way you can understand! Dan Platt, M.D. pulls the most relevant information out of the medical news and puts it into the correct context so that you can understand its importance for your disease.

Our goal is to share relevant medical news, information about clinical trials, and key takeaways from recent FDA approvals so that you can feel informed and empowered to get the best treatment possible.

Deskside with Dr. Dan articles are not offering medical advice but are created to provide information to empower decisions. You should always consult your oncology team with any questions that you might have.

Filtering

  • Acute Myeloid Leukemia
  • Chronic Myelomonocytic Leukemia
  • Lung Cancer
  • Lymphoma
  • Mesothelioma
  • Multiple Myeloma
  • Myelodysplastic Syndromes
  • Non-Hodgkin Lymphoma
  • Skin Cancer

  • Clinical Trial
  • Coronavirus
  • FDA Approval

FDA approves Tecentriq in combination with Cotellic and Zelboraf for patients with advanced skin cancer

Get Dr. Dan's medical perspective about the approval of Tecentriq in combination with Cotellic and Zelboraf for patients with advanced skin cancer.


FDA approves first cell-based gene therapy for adult patients with relapsed or refractory mantle cell lymphoma

Get Dr. Dan's medical perspective about the approval of the first cell-based gene therapy for adult patients with relapsed or refractory mantle cell lymphoma.


FDA approves oral combination of Dacogen and Cedazuridine for patients with myelodysplastic syndromes

Get Dr. Dan's medical perspective about the approval of the oral combination treatment of Dacogen and Cedazuridine for patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.


FDA grants accelerated approval to Gavreto, the second drug for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC)

Get Dr. Dan's medical perspective about the accelerated approval to Gavreto, the second drug for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC).


Page 2 of 2